Table 4.
Microbiological workup of the 43 patients enrolled in the study.
| CAPA Patients * | Aspergillus Respiratory Tract Colonisation Patients * | Total % (n) | |
|---|---|---|---|
| Positive microscopic examination in BAL |
4/16 |
0/7 |
17.4 (4/23) |
| Positive microscopic examination in NBL |
8/12 |
0/3 |
53.3 (8/15) |
| Positive GM in BAL | 15/16 | 0/7 | 65.2 (15/23) |
| Positive GM in NBL | 12/12 | 3/3 | 100 (15/15) |
| Positive GM in serum | 6/26 | 0/10 | 16.7 (6/36) |
| Positive culture for Aspergillus species in BAL |
7/16 |
0/7 |
30.4 (7/23) |
| Positive culture for Aspergillus species in NBL |
16/17 |
0/3 |
80 (16/20) |
| Positive PCR for Aspergillus genus | 4/8 | 7/7 | 73.3 (11/15) |
CAPA: Coronavirus disease 2019-associated pulmonary aspergillosis, GM: Galactomannan, BAL: Bronchoalveolar lavage, NBL: Non-directed broncoscopic lavage, PCR: Polymerase chain reaction, * classification of cases as CAPA or colonisation by Aspergillus according to the ECMM/ISHAM consensus criteria.